Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis (NASDAQ: CRIS) said 11 clinical sites are open for patient enrollment in its Phase 2 TakeAim CLL study of emavusertib plus zanubrutinib. The company reaffirmed dosing of the first five patients by end-July 2026 and expects data in December 2026. Stockholders approved a reverse stock split (1-for-5 to 1-for-25) to help regain Nasdaq bid-price compliance.
How this was made
The 30-second read
Why it matters
The company’s update reduces uncertainty on trial execution (sites opened; dosing of first five by end-July) while the reverse split approval introduces a near-term trading/psychology overhang tied to compliance and share-price mechanics.
Market read
This is a company-specific execution and corporate-action update that can move CRIS sentiment ahead of the next clinical milestone (first five patients dosed by end-July; data in December).
What to watch
Traders may be underweighting that the key clinical inflection (December data) is still months away, so the market may fade the news unless enrollment pace or early safety signals emerge.
Background
Curis is running a Phase 2 open-label TakeAim CLL study of emavusertib (CA-4948) plus zanubrutinib, and has been working to regain Nasdaq bid-price compliance.
Ticker impact
Curis says 11 clinical sites are open for patient enrollment in its TakeAim CLL Phase 2 study and reaffirms dosing timing through end-July 2026.
Near-term sentiment may improve on execution clarity, while the reverse split can pressure shares depending on ratio and liquidity expectations.
The release provides fresh, decision-relevant milestones (sites opened; dosing by end of July; data expected December) and a corporate action (stockholder approval of reverse split) that can affect trading/valuation mechanics.
Market effects
Adds incremental read-through for small-cap biotech execution in CLL combination regimens, but no direct competitive read-across is quantified here.
Primarily US small-cap biotech sentiment; limited broader regional impact.
Global relevance is modest because the update is operational and not a regulatory/efficacy datapoint.
Counterpoint
The reverse stock split approval signals ongoing Nasdaq compliance pressure; operational updates may not translate into near-term valuation support without efficacy data.
Key entities
- companyCuris, Inc.
NASDAQ-listed biotech (CRIS) running TakeAim CLL and seeking Nasdaq compliance via a reverse stock split.
- clinical_trialTakeAim CLL study
Phase 2 combination study evaluating emavusertib with zanubrutinib in CLL; dosing and data timing reaffirmed.
- corporate_actionReverse stock split
Stockholders approved a 1-for-5 to 1-for-25 reverse split; final ratio to be set by the board.
